Xtandi Seen to Delay Metastasis in Castration-resistant Prostate Cancer, Trial Shows

Xtandi Seen to Delay Metastasis in Castration-resistant Prostate Cancer, Trial Shows
Adding Xtandi (enzalutamide) to hormone therapy reduces the risk of cancer spreading in patients with non-metastatic castration-resistant prostate cancer (CRPC), new Phase 3 trial data shows. Additional results announced by Pfizer and Astellas Pharma, the drug developers, also show that the safety profile of Xtandi in this population is consistent with previous clinical trials. “Many prostate cancer patients

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *